Healthcare
CytomX Therapeutics Inc(CTMX)
Live Price
Offline$3.04
+3.05% today
1Y Change
+37.56%
Window
Jun 25, 2025 โ Jun 22, 2026
- Market Cap
- $690.00M
- Revenue Growth
- -44.8%
- EPS Growth
- -139.5%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 25, 2025 โ Jun 22, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CytomX Therapeutics Inc (CTMX) is a Healthcare stock with a market cap of $690.00M and listed on NASDAQ. The stock last traded around $3.04 and up 37.6% across the available one-year price window (Jun 25, 2025 โ Jun 22, 2026). Baseline metrics include revenue growth of -44.8%, EPS growth of -139.5%, a dividend yield of 0.0%. What stands out right now is revenue -44.8%, EPS -139.5%, free cash flow +12.4% with operating margin -29.4% and ROIC -20.3%. Valuation already assumes a fairly strong business story at price/sales 9.1. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CTMX price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-44.8% vs +7.6% peer median
Operating Margin
Below sector median
-29.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 11, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -44.8% and EPS is at -139.5%, with operating margin around -29.4%.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -17.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 11, 2026 | โ | +0.5% | -9.3% | -22.8% |
2026 Mar 16, 2026 | -175.0% | -19.3% | -33.9% | -32.7% |
2025 Nov 6, 2025 | -82.5% | -13.6% | -7.9% | -5.7% |
Benchmark Edge
CTMX vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CTMX
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CTMX Max Drawdown
-56.89%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CTMX and SPY.
Company Overview
CytomX Therapeutics Inc
NASDAQ
CytomX Therapeutics Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing novel conditionally activated biologics designed to be localized to the tumor microenvironment. The company's proprietary PROBODYยฎ therapeutic platform creates masked molecules that remain inactive in circulation and normal tissues but become activated within tumors, aiming to enhance anti-cancer efficacy while minimizing effects on healthy tissues. CytomX's clinical pipeline includes varsetatug masetecan, a masked antibody-drug conjugate targeting EpCAM for colorectal cancer, and CX-801, an interferon alpha-2b cytokine for melanoma and other oncology indications. The company also develops T-cell engagers and other immune-modulating therapies across multiple treatment modalities. CytomX maintains strategic research collaborations with major biopharmaceutical partners including Amgen, Astellas, Bristol Myers Squibb, Regeneron, and Moderna, focusing on advancing its platform technology across various cancer types. Based in South San Francisco, California, CytomX operates as a clinical-stage developer with a focus on expanding the therapeutic window for targets previously considered difficult to drug due to expression on normal tissues.
- Leadership
- Dr. Sean A. McCarthy DPHIL
- Employees
- 119
- Street Address
- 151 Oyster Point Boulevard, Suite 400
- Mailing
- South San Francisco, CA, 94080
- Region
- South San Francisco, CA, United States
- Last Updated
- May 8, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 9.1
- Price/Book
- 7.0
Growth
- Revenue
- -44.8%
- EPS
- -139.5%
- Free Cash Flow
- +12.4%
Profitability
- Gross Margin
- 99.3%
- Operating Margin
- -29.4%
- Net Margin
- -22.8%
- ROE
- -19.8%
- ROIC
- -20.3%
Balance Sheet
- Debt/Equity
- 0.04
- Current Ratio
- 3.09
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.